Annals of Surgical Oncology

, Volume 21, Issue 5, pp 1659–1664 | Cite as

Does Extracapsular Extension Impact the Prognosis of Papillary Thyroid Microcarcinoma?

  • Nathalie Chéreau
  • Camille Buffet
  • Christophe Trésallet
  • Frederique Tissier
  • Jean-Louis Golmard
  • Laurence Leenhardt
  • Fabrice Menegaux
Endocrine Tumors



Extracapsular (EC) extension is a pejorative factor in papillary thyroid carcinoma (PTC). However, the impact of EC extension in microcarcinoma (micro-pT3) remains controversial, and all pT3 patients are currently considered to be at high risk of recurrence.


This study sought to determine the risk of recurrence in patients with micro-pT3 and to compare their outcomes with other pT3 (macro-pT3) and low-risk patients.

Patients and Methods

All consecutive patients who received surgery for PTC in our department from January 1978 to December 2011 were included in this study. We compared three patient groups: micro-pT3 (≤10 mm with EC extension), macro-pT3, and low risk, including pT1a-b s N0-x, pT1a-b m N0-x, and pT2 N0-x. Total thyroidectomy was performed with lymph node (LN) dissection in most cases, and radioiodine therapy was administered as needed. The median follow-up period was 6.7 years.


A total of 2,482 patients were included in this study, including 178 micro-pT3 patients, 533 macro-pT3 patients, and 1,771 low-risk PTC patients. Recurrence was documented in 14 (7.9 %) micro-pT3 patients, 124 (23.3 %) macro-pT3 patients, and 36 (2 %) low-risk PTC patients. The micro-pT3 patients with LN metastases (N1) demonstrated a higher recurrence rate than the N0-x patients (14.8 vs. 4.8 %; p < 0.01), whereas the risk of recurrence among the T2 N0-x (5 %) and micro-pT3 N0-x (4.8 %) patients was similar (p = 0.95).


Micro-pT3 N1 patients are at high risk of recurrence and should be treated aggressively. Because the outcomes of the micro-pT3 N0-x patients were similar to those of the low-risk PTC patients (pT2 N0-x), we suggest that micro-pT3 N0-x should be treated in a similar manner, with low-dose iodine-131 and recombinant human thyrotropin.


Papillary Thyroid Carcinoma Total Thyroidectomy Multinodular Goiter Radioiodine Therapy Papillary Thyroid Carcinoma Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    National Cancer Institute. SEER cancer statistics review. 1975–2007.
  2. 2.
    Cramer JD, Fu P, Harth KC, Margevicius S, Wilhelm SM. Analysis of the rising incidence of thyroid cancer using the surveillance, epidemiology and end results national cancer data registry. Surgery. 2010;148:1147–52.PubMedCrossRefGoogle Scholar
  3. 3.
    Malandrino P, Pellegriti G, Attard M, Violi MA, Giordano C, Sciacca L, et al. Papillary thyroid microcarcinomas: a comparative study of the characteristics and risks factors at presentation in two cancer registries. J Clin Endocrinol Metab. 2013;98:1427–34.PubMedCrossRefGoogle Scholar
  4. 4.
    Yu XM, Wan Y, Sippel R, Chen H. Should all papillary microcarcinomas be aggressively treated? Ann Surg. 2011;254:653–60.PubMedCrossRefGoogle Scholar
  5. 5.
    Lombardi C, Bellantone R, De Crea C, Paladino NC, Fadda G, Salvatori M, et al. Papillary thyroid microcarcinoma: extrathyroidal extension, lymph node metastases, and risk factors for recurrence in a high prevalence of goiter area. World J Surg. 2010;34:1214–1221.PubMedCrossRefGoogle Scholar
  6. 6.
    Jung SP, Kim M, Choe JH, Kim JS, Nam SJ, Kim JH. Clinical implication of cancer adhesion in papillary thyroid carcinoma: clinicopathologic characteristics and prognosis analyzed with degree of extrathyroidal extension. World J Surg. 2013;37:1606–13.PubMedCrossRefGoogle Scholar
  7. 7.
    Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–4.PubMedCrossRefGoogle Scholar
  8. 8.
    Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JWA, Wiersinga W, The European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154:787–803.PubMedCrossRefGoogle Scholar
  9. 9.
    Borson-Chazot F, Bardet S, Bournaud C, et al. Recommandations pour la prise en charge des cancers thyroïdiens différenciés de souche vésiculaire. Ann Endocrinol. 2007;68 Suppl 2:S53–S94.Google Scholar
  10. 10.
    Borson-Chazot F, Bardet S, Bournaud C: Guidelines for the management of differentiated thyroid carcinomas of vesicular origin. Ann Endocrinol (Paris). 2008;69:472–86.PubMedCrossRefGoogle Scholar
  11. 11.
    Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. American Thyroid Association (ATA) guidelines taskforce on thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19;1167–214.PubMedCrossRefGoogle Scholar
  12. 12.
    Arora N, Turbendian HK, Scognamiglio T, Wagner PL, Goldsmith SJ, Zarnegar R, et al. Extrathyroidal extension is not all equal: implications of macroscopic versus microscopic extent in papillary thyroid carcinoma. Surgery. 2008;144:942–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Hu A, Clark J, Payne RJ, Eski S, Walfish PG, Freeman JL. Extrathyroidal extension in well-differentiated thyroid cancer: macroscopic vs microscopic as a predictor of outcome. Arch Otolaryngol Head Neck Surg. 2007;133:644–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Ito Y, Tomoda C, Uruno T, Miya A, Kobayashi K, Matsuzuka F, et al. Prognostic significance of extrathyroid extension of papillary thyroid carcinoma: massive but not minimal extension affects the relapse-free survival. World J Surg. 2006;30:780–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Neuhold N, Schultheis A, Hermann M, Krotla G, Koperek O, Birner P. Incidental papillary microcarcinoma of the thyroid-further evidence of a very low malignant potential: a retrospective clinicopathological study with up to 30 years of follow-up. Ann Surg Oncol. 2011;18:3430–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Suginati I, Toda K, Yamada K, Noriko Yamamoto N, Motoko Ikenaga M, Fujimoto Y. Three distinctly kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes. World J Surg. 2010;34:1222–31.CrossRefGoogle Scholar
  17. 17.
    Moon HJ, Kim E-K, Chung WY, Yoon JY, Kwak JY. Minimal extrathyroidal extension in patients with papillary thyroid microcarcinoma: is it a real prognostic factor? Ann Surg Oncol. 2011;18:1916–23.PubMedCrossRefGoogle Scholar
  18. 18.
    Hay ID, Hutchinson ME, Gonzalez-Losada T, et al. Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. Surgery. 2008;144:980–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Buffet C, Golmard JL, Hoang C, Trésallet C, Du Pasquier Fédiaevsky L, Fierrard H, et al. Scoring system for predicting recurrences in patients with papillary thyroid microcarcinoma. Eur J Endocrinol. 2012;167:267–75.PubMedGoogle Scholar
  20. 20.
    Besic N, Pilko G, Petric R, Hocevar M, Zgajnar J. Papillary thyroid microcarcinoma: prognostic factors and treatment. J Surg Oncol. 2008;97:221–5.PubMedCrossRefGoogle Scholar
  21. 21.
    Baudin E, Travagli JP, Ropers J, Mancusi F, Bruno-Bossio G, Caillou B, et al. Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience. Cancer. 1998;83:553–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Kim TY, Hong SJ, Kim JM, Kim WG, Gong G, Ryu JS, et al. Prognostic parameters for recurrence of papillary thyroid microcarcinoma. BMC Cancer. 2008;8:296.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Rivera M, Ricarte-Filho J, Tuttle RM, Ganly I, Shaha A, Knauf J, et al. Molecular, morphologic, and outcome analysis of thyroid carcinomas according to degree of extrathyroid extension. Thyroid. 2010;20:1085–93.PubMedCrossRefGoogle Scholar
  24. 24.
    Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC. Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab. 2004;89:3668–76.PubMedCrossRefGoogle Scholar
  25. 25.
    Schlumberger M, Catargi B, Borget I, Deandreis D, Zerdoud S, Bridji B, et al. Tumeurs de la Thyroïde Refractaires network for the Essai stimulation ablation equivalence Trial. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med. 2012;366:1663–73.PubMedCrossRefGoogle Scholar
  26. 26.
    Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, et al. Ablation with low dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med. 2012;366:1674–85.PubMedCrossRefGoogle Scholar
  27. 27.
    Hugo J, Robenshtok E, Grewal R, Larson SM, Tuttle RM. Recombinant human TSH-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence. Thyroid. 2012;22:1007–15.PubMedCrossRefGoogle Scholar
  28. 28.
    Elisei R, Schlumberger M, Driedger A, Reiners C, Kloos RT, Sherman SI, et al. Follow up of low risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. J Clin Endocrinol Metab. 2009:94:4171–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Castagna MG, Cevinini G, Theodoropoulou A, Maino F, Memmo S, Claudia C, et al. Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients. Eur J Endocrinol. 2013;169:23–9.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2014

Authors and Affiliations

  • Nathalie Chéreau
    • 1
  • Camille Buffet
    • 2
  • Christophe Trésallet
    • 1
  • Frederique Tissier
    • 3
  • Jean-Louis Golmard
    • 4
  • Laurence Leenhardt
    • 2
  • Fabrice Menegaux
    • 1
  1. 1.Department of General and Endocrine Surgery, Hôpital de la Pitié Salpêtrière, APHPUniversité Pierre et Marie Curie (Paris VI)ParisFrance
  2. 2.Department of Nuclear Medicine, Hôpital de la Pitié Salpêtrière, APHPUniversité Pierre et Marie Curie (Paris VI)ParisFrance
  3. 3.Department of Pathology, Hôpital de la Pitié Salpêtrière, APHPUniversité Pierre et Marie Curie (Paris VI)ParisFrance
  4. 4.Department of Biostatistics, Hôpital de la Pitié Salpêtrière, APHPUniversité Pierre et Marie Curie (Paris VI)ParisFrance

Personalised recommendations